NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction

ConditionSTEMI

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorSohag University

About this trial

Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide.

Atherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart disease It has been shown that A complex immune and inflammatory pathophysiological process is thought to be crucial for in the initiation and progression of atherosclerotic plaques.

Inflammation is one of the main mechanisms in the pathogenesis of atherosclerosis , Destabilization of chronic artery plaques and development of thrombosis, which are the main mechanisms in the pathophysiology of ST-segment elevation myocardial infarction (STEMI).

, and the interest to the evaluation of inflammatory biomarkers in coronary artery disease (CAD) has been increasing over the last decade .

Although numerous inflammatory markers, including troponin T/I, lactate dehydrogenase (LDH), and creatine kinase (CK-MB), are linked to worsened clinical outcomes in both ST elevation and non-ST elevation myocardial infarction (NSTEMI), there is an unmet need for a cost-effective biomarker for impoverished countries of the world .

The neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) ; has emerged as an important inflammatory markers for cardiovascular risk stratification.

And are relatively cheap inflammatory markers, can act as a bridge to mitigate the gap in assessing the cardiovascular risk and outcomes

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI.

Disqualifiers

Patients presenting with NSTEMI and unstable angina

Patients with any of these associated conditions that can affect NLR or CRP including

Inflammatory conditions such as collagen-vascular disorders

Acute or chronic infectious diseases.

Trial population

\- Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

CBC
Diagnostic test
Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
C-reactive protein
Diagnostic test
Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction

Treatment groups

100 Participants

are divided into 2 treatment groups

Group A: Elevated NLR and CRP level2 interventions

Group B: Normal NLR and CRP level2 interventions

Trial outcomes

Primary outcomes

Neutrophil-lymphocyte ratio

Explore the role of Neutrophil-lymphocyte ratio in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction

Time frame

6 months

C-reactive protein

C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction

Time frame

6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

Apply now